To optimize patient outcomes with anticoagulation for venous thromboembolism (VTE), it is
essential to assess patients for their recurrence risk. In this article, I will review the impact of …

Venous thromboembolism (VTE) is a disease, which often recurs. The recurrence risk is
highest in patients with unprovoked proximal deep-vein thrombosis (VT) or pulmonary …

Venous thromboembolism (VTE) is a common and chronic disease with a considerable risk
of recurrence. Patients with unprovoked (in the absence of a transient risk factor) VTE have a …

This study was conducted in patients treated for initial venous thromboembolism (VTE) for
approximately 6 months to enhance understanding of the risk factors to inform clinical …

Introduction VTE‐BLEED is a validated score for identification of patients at increased risk of
major bleeding during extended anticoagulation for venous thromboembolism (VTE). It is …

Acute venous thromboembolism (VTE) is a commonly diagnosed condition and requires
treatment with anticoagulation to reduce the risk of embolisation as well as recurrent venous …

Background: In patients with unprovoked venous thromboembolism (VTE), the optimal
duration of anticoagulation is anchored on estimating the risk of disease recurrence …

After the first venous thromboembolism (VTE), anticoagulant treatment duration should be
based on the balance between the risk of recurrence and bleeding. However, this decision …

Abstract Background and Aims Patients with unprovoked venous thromboembolism (VTE)
have a high recurrence risk, and guidelines suggest extended-phase anticoagulation. Many …

Recurrent venous thromboembolism (VTE) is associated with increased morbidity and
mortality. This risk is lowered by anticoagulation, with a large effect in the initial phase …